Thai Parliament to Evaluate Legalizing E-Cigarettes amid Strong Opposition

Regulations by 2FIRSTS.ai
Dec.12.2024
Thai Parliament to Evaluate Legalizing E-Cigarettes amid Strong Opposition
Thai parliament committee to evaluate legalizing e-cigarette sales amidst strong opposition, citing concerns about public health and underage use.

According to TPN, on December 11th, the Thai parliamentary committee will evaluate the issue of the legal sale of e-cigarettes in the country on December 12th. However, this action has faced strong opposition from civic groups, youth networks, and foundations, with a petition against legalization garnering nearly 600,000 signatures.


Thai education expert Sompong criticized the credibility of the committee, pointing out that the inclusion of representatives from the private sector related to the e-cigarette industry may lead to biased conclusions. He specifically highlighted aggressive marketing tactics targeting children under 8, which present e-cigarettes as fashionable and easily accessible products, especially through online platforms.


According to him, the number of young e-cigarette users has grown 2 to 3 times from 2015 to 2022. TPN media points out that this growth occurred during a period of complete e-cigarette ban. Supporters of legalization believe this indicates the failure of a total ban, and that reasonable regulation may be a better choice.


Supporters of legalization believe that this could increase tax revenue by regulating the current underground market. However, Cheddar Sompeng cites a study that claims the cost of treating e-cigarette-related illnesses is reportedly three times the tax revenue. He urges lawmakers not to focus solely on economic interests, but to carefully weigh all perspectives, emphasizing that if the decision to support legalization is made, it could cause long-term harm to public health and social integrity.


In addition, 14 medical associations unanimously oppose the legalization of e-cigarettes.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
On April 22, 2026, Philip Morris International released its first-quarter 2026 results. The report showed net revenues of $10.146 billion, up 9.1% year on year; adjusted diluted EPS of $1.96, up 16.0%; and smoke-free products accounting for 43% of total net revenues. Based on first-quarter performance, the company raised its 2026 full-year adjusted diluted EPS forecast to $8.36 to $8.51, or $8.11 to $8.26 excluding currency.
Apr.23 by 2FIRSTS.ai
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
    Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
The Shenzhen Tobacco Monopoly Bureau recently held the city’s 2026 e-cigarette regulation work conference to implement higher-level meeting requirements, review the city’s e-cigarette regulatory work in 2025 and during the 14th Five-Year Plan period, assess the current situation, and deploy the rollout of E-cigarette Regulatory System 2.0 across Shenzhen’s tobacco commercial system.
Apr.28 by 2FIRSTS.ai
Revised Tobacco Business Act to Take Effect in South Korea, Banning Online Sales of Liquid Vapes
Revised Tobacco Business Act to Take Effect in South Korea, Banning Online Sales of Liquid Vapes
South Korea’s Ministry of Health and Welfare will implement a partial revision of the Tobacco Business Act on April 24. The scope will expand from products made with “tobacco leaves” to all products manufactured with natural or synthetic nicotine. Synthetic nicotine liquid e-cigarettes, which had previously been treated as industrial products and were freely sold and advertised online, will from April 24 be subject to the same regulations as ordinary tobacco products.
Apr.23 by 2FIRSTS.ai
Exhibition Insights | Beyond Devices: What RELX’s Multi-Format Display Suggests About Category Expansion
Exhibition Insights | Beyond Devices: What RELX’s Multi-Format Display Suggests About Category Expansion
RELX’s booth in Prague brought together vaping devices, RELX-branded e-liquids, oral nicotine products and a nasal product concept in one display. Rather than centering the booth on a single hardware line, the company presented multiple product paths side by side.
Apr.20 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13